Stocks and Investing
Stocks and Investing
Thu, March 19, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 18, 2020
[ 12:00 AM ] - WOPRAI
Kennen MacKay Maintained (ABEO) at Buy with Decreased Target to $275 on, Mar 18th, 2020
Kennen MacKay of RBC Capital, Maintained "Abeona Therapeutics Inc." (ABEO) at Buy with Decreased Target from $350 to $275 on, Mar 18th, 2020.
Kennen has made no other calls on ABEO in the last 4 months.
There are 2 other peers that have a rating on ABEO. Out of the 2 peers that are also analyzing ABEO, 0 agree with Kennen's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Kennen
- Mani Foroohar of "SVB Leerink" Maintained at Buy and Held Target at $150 on, Monday, February 10th, 2020
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy with Decreased Target to $275 on, Monday, December 30th, 2019